Hemogenyx Raises £3m to Accelerate HG-CT-1 Trials and Early Commercialisation

The latest announcement is out from HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ).

Hemogenyx Pharmaceuticals has raised £3 million from a small group of institutional investors via a direct subscription of 374,532 new shares to accelerate clinical development of its CAR-T therapy HG-CT-1. The capital will primarily fund Phase I trials in adult relapsed or refractory acute myeloid leukaemia and extend the programme into paediatric patients, strengthening the company’s position in addressing a significant unmet oncology need.

The company is also advancing an early commercialisation strategy for HG-CT-1 through Estonia’s hospital exemption pathway, having now established the necessary manufacturing hardware and infrastructure. In partnership with Cellin Technologies, Hemogenyx plans to begin technology transfer for local production, while the new shares move to admission on the London Stock Exchange and increase the company’s total voting rights to 6,799,961 shares.

Management frames this dual track of clinical progress and early commercial readiness as a key value driver that could accelerate patient access to HG-CT-1. The fundraising and Estonian manufacturing milestones are presented as important steps in de-risking the project and potentially enhancing returns for investors and outcomes for AML patients, including children.

Spark’s Take on HEMO Stock

According to Spark, TipRanks’ AI Analyst, HEMO is a Neutral.

The score is held down primarily by very weak financial performance (no revenue, ongoing losses and cash burn, and higher balance-sheet risk from lower equity and increased leverage). Technicals provide some offset with strong recent momentum, but overbought indicators add near-term risk, and valuation support is limited due to a negative P/E and no dividend yield.

To see Spark’s full report on HEMO stock, click here.

More about HemoGenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals plc is a London-headquartered, clinical-stage biopharmaceutical company listed on the LSE and focused on developing new medicines for blood and autoimmune diseases. Through its UK and US operations, the group is advancing several complementary product candidates and platform technologies, including its proprietary CAR-T cell therapy HG-CT-1 targeting acute myeloid leukaemia.

Average Trading Volume: 27,564

Technical Sentiment Signal: Buy

Current Market Cap: £51.79M

See more data about HEMO stock on TipRanks’ Stock Analysis page.